Abstract
A PHASE 3 RANDOMISED CONTROLLED TRIAL TO COMPARE CT-P13 WITH INFLIXIMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: 54 WEEK RESULTS FROM THE PLANETRA STUDY
Full text
Background: CT-P13 is a biosimilar product of infliximab (INX). Data up to week 30 has been reported at EULAR 2012.
Objectives: To compare the efficacy and safety of CT-P13 and INX in active rheumatoid arthritis (RA) patients up to week 54.
Methods: Patients with active RA (1987 ACR criteria) and inadequate response to methotrexate (MTX) were randomised (1:1) to receive either CT-P13 (3mg/kg) or INX (3mg/kg) at weeks 0, 2, 6 and then every 8 weeks up to week 54 in combination with MTX (12.5–25mg/week).
Results: Of 606 patients randomised at baseline, 457 patients were treated up to week 54. At week 54, ACR20 was highly similar between groups (CT-P13, 57.0% [172/302]; INX, 52.0% [158/304]; 95% CI: -0.03–0.13). ACR50 and ACR70 scores were also comparable between groups (CT-P13, 33.1% and 16.2%; INX, 31.6% and 15.1%, respectively). In the CT-P13 and INX groups respectively, 26.4% and 27.8% of patients reached remission with DAS28-CRP; additionally, 14.3% and 14.8% reached low disease activity compared to approximately 80% high disease activity in both groups at baseline. The proportion of patients testing positive for anti-drug antibodies (ADAs) was comparable between CT-P13 (52.3%) and INX (49.5%). More patients with negative ADA results achieved ACR20 responses (CT-P13, 73.9%; INX, 67.2%) compared with patients with positive results (CT-P13, 53.2%; INX, 48.1%). Total Sharp scores at baseline and week 54 were comparable (CT-P13, 104.6 and 70.4; INX, 103.6 and 73.0). Cmax of CT-P13 or INX at all doses ranged from 66.1µg/mL–112.2µg/mL and 60.3µg/mL–104.5µg/mL, respectively. The safety profiles of CT-P13 and INX were also comparable (table).
Conclusions: CT-P13 showed comparable efficacy and PKs to those of INX up to week 54. CT-P13 was well tolerated with a safety profile comparable to that of INX up to week 54.
References:
1.Yoo D et al. A randomized, double-blind, phase 3 study demonstrates clinical equivalence of CT-P13 to infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 3):359.
Disclosure of Interest: D. H. Yoo Consultant for: CELLTRION Inc., A. Racewicz Grant/research support from: CELLTRION Inc., J. Brzezicki Grant/research support from: CELLTRION Inc., R. Yatsyshyn Grant/research support from: CELLTRION Inc., E. Tobias Arteaga Grant/research support from: CELLTRION Inc., A. Baranauskaite Grant/research support from: CELLTRION Inc., C. Abud-Mendoza Grant/research support from: CELLTRION Inc., S. Navarra Grant/research support from: CELLTRION Inc., Consultant for: Pfizer Ltd., Speakers bureau: CELLTRION Inc., R. Eullaran Grant/research support from: CELLTRION Inc., V. Kadinov Grant/research support from: CELLTRION Inc., I. Goecke Sariego Grant/research support from: CELLTRION Inc., P. Byrne Grant/research support from: CELLTRION Inc., W. Park Consultant for: CELLTRION Inc., S. J. Lee Consultant for: CELLTRION Inc., Employee of: CELLTRION Inc., H. U. Kim Employee of: CELLTRION Inc., U. Müller-Ladner Speakers bureau: CELLTRION Inc.Citation: , volume 72, supplement s3, year 2013, page Session: Abstract session: RA: anti-TNF therapy
( )
16 organizations
Organization
NZOZ Osteo-Medic, BialystokOrganization
Wojewodzki Szpital Zespolony, Elbląg, PolandOrganization
Hospital Militar Central, Bogota, ColombiaOrganization
Kaunas Medical Univ. Hospital, Kaunas, LithuaniaOrganization
St. Luke’s Medical Center, Quezon CityOrganization
Chong Hua Hospital, Cebu City, PhilippinesOrganization
Univ. Hospital St. Marina, Varna, BulgariaOrganization
Prosalud y cia Ltda, Santiago, ChileOrganization
Inha Univ. Hospital, Incheon, Korea, Republic OfOrganization
CELLTRION, Incheon, Korea, Republic OfOrganization
Univ. of New Mexico, Albuquerque, United States